Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,047 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immuno-Oncology for Gynecologic Malignancies.
How JA, Patel A, Jazaeri AA. How JA, et al. Among authors: patel a. Adv Exp Med Biol. 2021;1342:193-232. doi: 10.1007/978-3-030-79308-1_6. Adv Exp Med Biol. 2021. PMID: 34972966 Review.
Immuno-oncology for Gynecologic Malignancies.
How J, Patel A, Jazaeri A. How J, et al. Among authors: patel a. Adv Exp Med Biol. 2020;1244:149-182. doi: 10.1007/978-3-030-41008-7_7. Adv Exp Med Biol. 2020. PMID: 32301014 Review.
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Hinchcliff EM, et al. Among authors: patel a. Cancer. 2024 Apr 1;130(7):1061-1071. doi: 10.1002/cncr.35126. Epub 2023 Nov 27. Cancer. 2024. PMID: 38009662 Clinical Trial.
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.
Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F. Maiti A, et al. Among authors: patel a. Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):142-148.e1. doi: 10.1016/j.clml.2018.12.009. Epub 2018 Dec 20. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30635233 Clinical Trial.
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. Short NJ, et al. Among authors: patel a. Am J Hematol. 2019 Jan;94(1):74-79. doi: 10.1002/ajh.25318. Epub 2018 Nov 15. Am J Hematol. 2019. PMID: 30328139 Free PMC article. Clinical Trial.
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Boddu P, et al. Among authors: patel a. Front Oncol. 2018 Sep 24;8:369. doi: 10.3389/fonc.2018.00369. eCollection 2018. Front Oncol. 2018. PMID: 30319961 Free PMC article.
SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
Ogger PP, Martín MG, Jang S, Zhou J, Brown J, Sukhova K, Furnon W, Patel AH, Cowton V, Palmarini M, Barclay WS, Johansson C. Ogger PP, et al. Among authors: patel ah. Front Immunol. 2024 Apr 29;15:1383612. doi: 10.3389/fimmu.2024.1383612. eCollection 2024. Front Immunol. 2024. PMID: 38742107 Free PMC article.
14,047 results
You have reached the last available page of results. Please see the User Guide for more information.